Accueil/Actions/PMVP

PMVP

USD

PMV Pharmaceuticals Inc. Common Stock

$1.340-0.040 (-2.899%)

Prix en Temps Réel

Healthcare

Biotechnologie

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$1.380

Haut

$1.430

Bas

$1.320

Volume

0.37M

Fondamentaux de l'Entreprise

Capitalisation Boursière

71.0M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

1.26M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $0.81Actuel $1.340Haut $1.84

Actualités Connexes

24 oct. 2025 · 15:39

GlobeNewswire

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ovarian, lung, breast,

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

13 oct. 2025 · 20:01

GlobeNewswire

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oral presentation to highlight initial data from ongoing pivotal Phase 2 study of rezatapopt, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors harboring a TP53 Y220C